帕金森病中失声症的患病率和治疗:一个跨部门的国家数据库研究
Vicki Liu1, Dori Smith2, Helena Yip2
1College of Medicine-Tucson University of Arizona Tucson Arizona USA.
Laryngoscope investigative otolaryngology
|May 15, 2025
概括
帕金森病 (PD) 经常导致语音障碍,但大多数患者没有接受语音治疗. 这项研究发现严重的诊断不足和治疗不足,女性性别和西班牙裔族裔与语音护理的机会较少有关.
科学领域:
- 神经学 神经学
- 语音语言病理学 语言病理学
- 公共卫生 公共卫生
背景情况:
- 帕金森病 (PD) 经常涉及言语和声音障碍,影响高达89%的个人.
- 尽管发病率很高,但只有很小一部分 (3%-4%) 的PD患者接受言语和语音治疗.
- 需要了解PD中听力障碍诊断和治疗的全国范围.
研究的目的:
- 为了确定帕金森病患者的听力障碍的患病率.
- 评估语音评估和PD语音障碍症治疗的发生率.
- 确定国家PD患者群体在语音护理获取方面的潜在差异.
主要方法:
- 使用了NIH我们所有人的研究计划数据库.
- 使用ICD-9和ICD-10代码识别了PD和音障病例.
- 通过CPT代码分析诊断语音护理 (喉腔镜检查,语音评估) 和治疗 (语音增强,语音治疗).
- 使用后勤回归来检查语音护理访问与人口统计/社会经济因素之间的关联.
主要成果:
- 在1968年的PD患者中,13.1%被诊断为听障;85.5%没有接受语音护理.
- 在接受护理的人中,13.4%接受了诊断评估,6.3%接受了治疗.
- 女性性别 (aOR=0.62) 和西班牙裔种族 (aOR=0.44) 与获得语音护理的几率明显较低有关.
结论:
- 在全国的帕金森病患者中,听力障碍的诊断不足 (13.1%) 和治疗不足 (6.3%).
- 在语音护理获取方面存在显著的差异,特别是在女性和西班牙裔PD患者中.
- 这些发现突出了改善PD语音障碍的查,诊断和治疗的迫切需要.
相关概念视频
Parkinson's Disease: Treatment
163
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
163
Parkinson's Disease: Overview
360
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
360
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
110
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
110


